ITT Population
tumor, Tumor
DISEASE, TUMOR, TUMOR
Forty-four (77.2%) patients in the ITT population with target lesions at baseline and at least one imaging examination after treatment were evaluable for efficacy (Tumor response to senaparib and evaluation of clinical benefit (dose-escalation and dose-expansion periods, ITT populations; 




Abbreviations: BID, twice daily; C1, confidence interval; DCR, disease control rate; DOR, duration of response; ITT, intent to treat; NR, not reached; ORR, objective response rate; PFS, progression-free survival; QD, once daily.Waterfall plot of best change in target lesions in the evaluable ITT population (dose escalation and dose expansion) showing tumor type and BRCA